Endo Health Solutions

From Wikipedia, the free encyclopedia
  (Redirected from Endo Pharmaceuticals)
Jump to: navigation, search
Endo Health Solutions Inc.
Type Public
Traded as NASDAQENDP
Industry Pharmaceutical
Headquarters Chadds Ford, Pennsylvania
Website www.endo.com

Endo Health Solutions Inc. is an American pharmaceutical company. It was created as a result of a management buyout from DuPont Merck in 1997. Three DuPont Merck executives (Carol A. Ammon, Chairman, President & CEO, and Mariann T. MacDonald, Executive Vice President, Operations, along with another colleague) purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including Percocet, Percodan, and Opana. The new company was called "Endo Pharmaceuticals Inc." On 23 May 2012, Endo's shareholders approved a resolution to change the company's name to "Endo Health Solutions Inc."[1][2]

Endo acquired Algos Pharmaceutical Corporation through a merger in July 2000 and began to trade publicly (NASDAQENDP). Endo successfully completed a secondary offering for a total of 12,925,000 shares of its common stock in Oct 2001. The net proceeds were used to pay existing bank debt.

Endo is a specialty pharmaceutical company engaged in the research, development, sale and marketing of prescription pharmaceuticals used primarily to treat and manage pain.

Endo contracts some production and quality control testing from Novartis, at the Novartis manufacturing facility in Lincoln, Nebraska. Prior to its December 2011 shutdown, this particular Novartis manufacturing facility made all Excedrin distributed in the United States.

Personnel[edit]

Products[edit]

Source:[4]

Endo Pharmaceuticals once had the United States marketing rights for the FDA-approved Synera anesthetic patch for needle procedures. The agreement of 6 January 2006 for Endo Pharmaceuticals to market Synera (lidocaine plus tetracaine patch) was terminated on 31 July 2008.  Endo is no longer involved with the Synera patch in the United States.  Zars Pharmaceuticals was the patent holder for Synera.[5] The rights to Synera passed to Nuvo Research of Canada in May 2011 upon the acquisition of ZARS Pharmaceuticals by Nuvo Research.[6] Upon its purchase of Paladin Labs of Montreal, Endo once again became involved with the Synera patch by acquiring the rights to market Synera in Canada upon the approval of the Synera patch by Health Canada.[7][8]


Acquisitions[edit]

In 2009, Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology.[9] The company entered the male hypogonadism market later in 2010 with FORTESTA 2% gel.[9]

In November 2013, Endo agreed to purchase Paladin Labs Inc for approximately $1.6 billion, in order to gain access to the Canadian market as well as expand into emerging markets.[8]

Acquisition attempts[edit]

In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for US$105 million.[10] However, Teva prevailed in this acquisition with a substantially higher bid.[11]

See also[edit]

References[edit]

  1. ^ "Endo | Press Releases". endo.com. 2012. Retrieved May 23, 2012. 
  2. ^ Lopatto, Elizabeth (2012-03-01). "Endo Pharmaceuticals to Change Name to Endo Health Solutions". Bloomberg News. Archived from the original on 2012-03-04. 
  3. ^ a b c Staff (2006-12-06). "Endo Health Solutions Inc.". Delaware News Journal. Retrieved 2006-12-06. [dead link]
  4. ^ "Product Listing". Endo Pharmaceuticals. 2006. Retrieved 2006-12-06. 
  5. ^ http://www.wikinvest.com/stock/Endo_Pharmaceuticals_Holdings_%28ENDP%29/Zars%20Pharma
  6. ^ http://www.prnewswire.com/news-releases/nuvo-research-completes-its-acquisition-of-zars-pharma-121767618.html
  7. ^ http://www.marketwired.com/press-release/paladin-labs-nuvo-research-sign-canadian-license-agreement-synera-loan-agreement-tsx-plb-1662022.htm
  8. ^ a b Bloomberg (2013-11-04). "Endo to buy Paladin labs". Bloomberg. Retrieved 2013-11-04. 
  9. ^ a b Associated Press (2009-01-06). "Endo to buy Indevus". The Boston Globe. Retrieved 2009-06-28. 
  10. ^ "Endo to Purchase NuPahte for $150M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper) 34 (2). January 15, 2014. p. 10. 
  11. ^ "Teva Outbids Endo, Acquires NuPathe for $144M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper) 34 (4). February 15, 2014. p. 10. 

External links[edit]